CN116350535A - Hair-fixing and developing composition and application thereof - Google Patents
Hair-fixing and developing composition and application thereof Download PDFInfo
- Publication number
- CN116350535A CN116350535A CN202310304218.5A CN202310304218A CN116350535A CN 116350535 A CN116350535 A CN 116350535A CN 202310304218 A CN202310304218 A CN 202310304218A CN 116350535 A CN116350535 A CN 116350535A
- Authority
- CN
- China
- Prior art keywords
- hair
- percent
- composition
- oxide
- fixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 210000004209 hair Anatomy 0.000 claims abstract description 52
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims abstract description 24
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 102000008186 Collagen Human genes 0.000 claims abstract description 20
- 108010035532 Collagen Proteins 0.000 claims abstract description 20
- 229920001436 collagen Polymers 0.000 claims abstract description 20
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 claims abstract description 17
- OQZGLXOADHKTDN-UHFFFAOYSA-N 1-oxidopyrimidin-1-ium Chemical class [O-][N+]1=CC=CN=C1 OQZGLXOADHKTDN-UHFFFAOYSA-N 0.000 claims abstract description 17
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims abstract description 17
- 241000530268 Lycaena heteronea Species 0.000 claims abstract description 17
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 15
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 15
- 241000209140 Triticum Species 0.000 claims abstract description 13
- 235000021307 Triticum Nutrition 0.000 claims abstract description 13
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 12
- FDHNLHLOJLLXDH-JIYHLSBYSA-N (e)-3-(3-hydroxy-4-methoxyphenyl)-1-[2-hydroxy-6-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxyphenyl]prop-2-en-1-one Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C(=O)C(C(=C1)OC)=C(O)C=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 FDHNLHLOJLLXDH-JIYHLSBYSA-N 0.000 claims abstract description 12
- 229940083957 1,2-butanediol Drugs 0.000 claims abstract description 12
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 12
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 12
- 229930003756 Vitamin B7 Natural products 0.000 claims abstract description 12
- 229960005305 adenosine Drugs 0.000 claims abstract description 12
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940076640 hesperidin methylchalcone Drugs 0.000 claims abstract description 12
- 229940101267 panthenol Drugs 0.000 claims abstract description 12
- 235000020957 pantothenol Nutrition 0.000 claims abstract description 12
- 239000011619 pantothenol Substances 0.000 claims abstract description 12
- 239000011735 vitamin B7 Substances 0.000 claims abstract description 12
- 235000011912 vitamin B7 Nutrition 0.000 claims abstract description 12
- 244000269722 Thea sinensis Species 0.000 claims abstract 4
- 230000003779 hair growth Effects 0.000 claims description 22
- 239000011259 mixed solution Substances 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 9
- 230000001256 tonic effect Effects 0.000 claims description 9
- -1 2- [ (dimethylamino) methyl ] -1-oxo-4-phenyl-1-pyrimidinium-5-ol Chemical compound 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- DFEZJQWEUXUFNU-UHFFFAOYSA-N 2,6-bis[(dimethylamino)methyl]-1-oxido-4-phenylpyrimidin-1-ium-5-ol Chemical compound CN(C)CC1=[N+]([O-])C(CN(C)C)=NC(C=2C=CC=CC=2)=C1O DFEZJQWEUXUFNU-UHFFFAOYSA-N 0.000 claims description 6
- RZLLYRFQUKPWHH-UHFFFAOYSA-N 1-oxido-4,6-diphenylpyrimidin-1-ium Chemical compound [O-][N+]1=CN=C(C=2C=CC=CC=2)C=C1C1=CC=CC=C1 RZLLYRFQUKPWHH-UHFFFAOYSA-N 0.000 claims description 5
- AKPVYPUCEJKEHG-UHFFFAOYSA-N 1-oxido-4-phenylpyrimidin-1-ium-5-ol Chemical compound OC1=C[N+]([O-])=CN=C1C1=CC=CC=C1 AKPVYPUCEJKEHG-UHFFFAOYSA-N 0.000 claims description 5
- WDSYOQFVRLVNIZ-UHFFFAOYSA-N 2-methyl-1-oxido-4-phenylpyrimidin-1-ium Chemical compound C1=[N+]([O-])C(C)=NC(C=2C=CC=CC=2)=C1 WDSYOQFVRLVNIZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000003656 anti-hair-loss Effects 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 210000003780 hair follicle Anatomy 0.000 abstract description 45
- 230000000694 effects Effects 0.000 abstract description 32
- 230000035755 proliferation Effects 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 2
- 201000004384 Alopecia Diseases 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 23
- 231100000360 alopecia Toxicity 0.000 description 18
- 230000000844 anti-bacterial effect Effects 0.000 description 16
- 241001122767 Theaceae Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 210000004761 scalp Anatomy 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 210000000130 stem cell Anatomy 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 102000001307 androgen receptors Human genes 0.000 description 7
- 108010080146 androgen receptors Proteins 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 230000003676 hair loss Effects 0.000 description 7
- 208000024963 hair loss Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 description 7
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 6
- 201000002996 androgenic alopecia Diseases 0.000 description 6
- YTKGAYFHUZTLCI-UHFFFAOYSA-N 3-hydroxy-2-iminopyrimidin-4-amine Chemical compound NC1=CC=NC(=N)N1O YTKGAYFHUZTLCI-UHFFFAOYSA-N 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 241000555676 Malassezia Species 0.000 description 5
- 229960003473 androstanolone Drugs 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- 108010011485 Aspartame Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000186427 Cutibacterium acnes Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- RSMJUJQJXRIIQS-UHFFFAOYSA-N NC1=CC(=NC=[N+]1[O-])N Chemical class NC1=CC(=NC=[N+]1[O-])N RSMJUJQJXRIIQS-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 229940055019 propionibacterium acne Drugs 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000003797 telogen phase Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 2
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003658 preventing hair loss Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000027756 respiratory electron transport chain Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- LKOVPWSSZFDYPG-WUKNDPDISA-N trans-octadec-2-enoic acid Chemical compound CCCCCCCCCCCCCCC\C=C\C(O)=O LKOVPWSSZFDYPG-WUKNDPDISA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- 102100033875 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Human genes 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000640851 Homo sapiens 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Proteins 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- BAEWURLBOZSGIA-UHFFFAOYSA-N NC1=NC=CC=[N+]1[O-] Chemical compound NC1=NC=CC=[N+]1[O-] BAEWURLBOZSGIA-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to the technical field of medical, dental or dressing preparations, and in particular discloses a hair-fixing and developing composition and application thereof. The hair-fixing and developing composition comprises the following raw materials: 1, 2-butanediol, p-hydroxyacetophenone, dipotassium glycyrrhizinate, vitamin H, pyrimidine oxide derivatives, adenosine, nicotinamide, panthenol, hesperidin methyl chalcone, hydrolyzed wheat protein, blue copper peptide, acetyl tetrapeptide-5, doctor tea, type 17 collagen and the balance of water. The composition can improve the environment around hair follicle, strengthen hair follicle, and stabilize hair root; can also promote the proliferation of papilla cells, and finally achieve the effect of fixing and developing hair.
Description
Technical Field
The invention relates to the technical field of medical, dental or dressing preparations, in particular to a hair-fixing and developing composition and application thereof.
Background
With the increase of working pressure, the acceleration of life rhythm, environmental influence, hair-dyeing, hair-waving and other hairdressing modeling products, hair-loss patients increase year by year and show signs of younger age, the young people become the dominant force of hair loss, and a safe and effective hair-loss prevention and hair-growing product is urgently needed to be searched. Types of hair loss can be categorized as: androgenic alopecia (Androgenic alopecia, AGA), nervous alopecia, chemical alopecia, physical alopecia, senile alopecia, and pathological alopecia. Among the types of hair loss that are commonly seen clinically are androgenic alopecia. Androgenic alopecia, also known as seborrheic alopecia, is also known as male pattern alopecia. The clinical symptoms are that the hair of the head of a patient is greasy, the hair follicle is blocked and atrophic, the hairline of the forehead moves backwards, and the hair at the top becomes easier to fall off after a long time. In vivo androgens in men are mainly Testosterone (T) produced in the testes, which can be catalytically reduced to Dihydrotestosterone (DHT) by type II 5α reductase present in the scalp, hair follicle and surrounding tissues thereof, and Dihydrotestosterone in the scalp competes with Testosterone for binding to the androgen receptor (Androgenic receptor, AR) located at the hair follicle, wherein Dihydrotestosterone is more likely to bind to the androgen receptor than Testosterone, and Dihydrotestosterone can aggregate at the hair follicle after binding to the androgen receptor, and blockage affects normal hair follicle growth. The cause of androgenic alopecia is complex, the mechanism is not completely studied and is mainly considered to have the following points in the current study: the body has over-high androgen content, the activity of androgen receptor is increased, the over-expression of androgen receptor is carried out, and the activity of II type 5 alpha reductase is increased. The above points result in an increased amount of testosterone converted to dihydrotestosterone in the scalp compared with normal persons in patients with androgenic alopecia, and the complex formed by the coupling of dihydrotestosterone and androgen receptor is accumulated at the hair follicle, severely blocks the hair follicle, and the hair follicle is atrophic due to the inability to absorb nutrients from surrounding tissues, thus shortening the growth cycle of the hair follicle, affecting the hair growth of the patient, leading to hair thinning and eventually alopecia.
In addition to the hormonal effects, sebum secreted by the scalp is acted upon by microorganisms to produce fatty acids, stimulating the scalp to produce inflammation, wherein the microorganism that plays the primary role is malassezia. Triacylglycerols secreted by sebaceous glands are hydrolyzed under the action of esterases, consuming saturated fatty acids, releasing irritating unsaturated fatty acids (e.g. octadecenoic acid), resulting in a decrease in the degree of densification of the skin adipose tissue, thus affecting the skin barrier function. Yet another genus is Propionibacterium acnes, accounting for 99.7% of Propionibacterium scalp. When the hair follicle is blocked, the sebaceous glands cannot normally discharge sebum, the oxygen content is reduced, so that anaerobic propionibacteria are excessively propagated, and free fatty acid is released by decomposing lipid, so that the skin barrier is destroyed. Propionibacterium acnes is a more efficient source of free fatty acids on the skin surface than malassezia, and in addition, the various extracellular enzymes produced by propionibacterium acnes can directly damage tissues and stimulate the skin to produce inflammatory changes. In addition to inflammation caused by microorganisms, excessive lipids are oxidized by external ultraviolet rays and PM2.5 pollution to generate malondialdehyde, and squalene is oxidized to damage an outermost anti-line-water lipid membrane of a skin barrier structure, so that barrier function is reduced, and finally inflammation and alopecia symptoms are caused.
Chinese patent 202010135298.2 discloses a hair loss preventing and hair growing composition and a preparation method thereof. The hair loss preventing and growing composition comprises the following components: 0.001 to 10 parts of oligopeptide-29 and 0.001 to 10 parts of any one or two of decapeptide-4, 0.8 to 50 parts of traditional Chinese medicine extract and 0.5 to 5 parts of nicotinamide VB 3 0.5 to 5 parts of trehalose, 0.1 to 0.5 part of allantoin, 1 to 10 parts of sodium oleate, 1 to 10 parts of glycerin, 0.5 to 1 part of ethylhexyl glycerin, 1 to 10 parts of wild soybean oil, 1 to 10 parts of hydrogenated lecithin, 0.5 to 1 part of phenoxyethanol, 30 to 90 parts of water, 0.1 to 2 parts of ammonium acryloyldimethyl taurate and behenpolyether-25 methacrylate cross-linked polymer. The composition has effects of promoting hair growth and reducing alopecia.
Chinese patent 201810888404.7 discloses a hair tonic for preventing alopecia, comprising: humectant, antidandruff antipruritic, solvent, amino acid, nutritional supplement, oil control agent, nicotinamide, diaminopyrimidine oxide, ethanol, folium Platycladi extract, radix Ginseng extract, tween-20, antiseptic, essence, water, etc. The invention also discloses a preparation method of the composite. In the formula of the hair growth liquid, various active components are mutually compatible and cooperated, so that the hair growth liquid has good hair growth effect, has good effects on hair care and skin nutrition, is simple in preparation method, low in cost, strong in stability, small in side effect, free of irritation and suitable for wide application.
Most of the hair-loss preventing and hair-growing products in the prior art adopt traditional Chinese medicine extracts or hair-growing mixtures extracted from plant sources, but the stability of the plant extract components is poor, and the plant extract components are easy to decompose or react with other components in a product system chemically, so that the stability of the product is reduced; on the other hand, the plant extract has complex composition, non-single composition and a lot of impurities, the content of the true effective components of each batch cannot be ensured to reach the standard due to the unclear determined composition components, and the diaminopyrimidine oxide has good curative effect as a disclosed alopecia preventing agent, but has poor water solubility, and most products use water as a solvent, so that the efficacy of the products is greatly influenced.
Disclosure of Invention
In view of the above-mentioned drawbacks of the prior art, the present invention aims to provide a hair-setting composition capable of strengthening hair follicle, stabilizing hair root and improving the activity of hair follicle cells and its application.
The basic idea of the invention is that hydrophilic groups on pyrimidine oxide derivative structure are utilized to promote the water solubility, in addition, benzene rings in the derivative promote the antibacterial property, and electron withdrawing groups lead to the enhancement of antibacterial activity, so that the effects of preventing hair loss, growing hair, resisting bacteria and removing dandruff can be achieved when the composition is applied to hair-setting and hair-growing compositions.
The invention is completed according to the above, and the specific technical scheme of the invention is as follows:
a hair-fixing and developing composition comprises the following components in percentage by mass: 0.1 to 10 percent of 1, 2-butanediol, 0.1 to 1 percent of p-hydroxyacetophenone, 0.01 to 1 percent of dipotassium glycyrrhizinate, 0.001 to 1 percent of vitamin H, 0.1 to 1.5 percent of pyrimidine oxide derivative, 0.05 to 5 percent of adenosine, 0.05 to 10 percent of nicotinamide, 0.01 to 10 percent of panthenol, 0.05 to 3 percent of hesperidin methyl chalcone, 0.001 to 5 percent of hydrolyzed wheat protein, 0.001 to 5 percent of blue copper peptide, 0.001 to 5 percent of acetyl tetrapeptide-5, 0.001 to 10 percent of doctor tea, 0.001 to 20 percent of 17-type collagen and the balance of water.
The pyrimidine oxide derivative is at least one of 2,6-bis (dimethylaminomethyl) -4-phenyl-5-hydroxypyrimidine 1-oxide, 2-methyl-4-phenylpyrimidine 1-oxide, 4, 6-diphenylpyrimidine-1-oxide, 4-phenyl-5-hydroxypyrimidine 1-oxide and 2- [ (dimethylamino) methyl ] -1-oxo-4-phenyl-1-pyrimidinium-5-ol.
The anti-hair loss active diaminopyrimidine oxide (Kopexil) is an active substance for treating alopecia, which is proposed by the company of elegance, has a structure similar to minoxidil, and is poorly water-soluble, but is soluble in organic solvents such as glycerin and propylene glycol. It has been proved by research that it can interfere with the production of mature collagen by fibroblasts and prevent the deposition of mature collagen by inhibiting the expression of lysine hydroxylase mRNA, avoiding the hardening and shrinking of peripheral hair follicles, preventing alopecia, but most solid developmental products are not possible to add organic solvents but water as solvents because they need to be directly used on the scalp, and diaminopyrimidine oxides themselves have very limited water solubility, and in order to enable consumers to achieve effects quickly after using the products, some products may be added with excessive diaminopyrimidine oxides to achieve effects, so that the maximum use limit of diaminopyrimidine oxides is clearly specified as 1.5% in the national "cosmetic safety technical Specification (2015 edition), but this also affects the exertion of their effects. In the invention, the hydrophilic group on pyrimidine ring of pyrimidine oxide derivative can improve the defect of poor water solubility, so that the active ingredient can better play a role in the hair-fixing and developing composition, the phenyl group connected with pyrimidine ring can enhance the antibacterial activity of the derivative, the antibacterial principle is that the active substance can cause the rupture of the cell wall or cell membrane of microorganism or the action of certain enzyme or metabolic substance generated by microorganism cell, so that the enzyme inactivation or metabolic chain interruption is caused, the electron transfer plays a very important role in the process, the pyrimidine oxide can provide electrons and also accept electrons, and the conjugation effect formed between pyrimidine ring and benzene ring after introducing the benzene ring promotes the activity, so that the active ingredient can inhibit the growth of malassezia, thereby achieving the effect of anti-dandruff and anti-drop. The hair-fixing and developing composition maintains the functions of hair follicle stem cells by adding 17-type collagen, and the linear aspartame extract contained in the doctor tea can inhibit the apoptosis of hair follicle stem cells and hair papilla cells, improve the environment around hair follicles and strengthen hair follicles; the growth period of hair follicle is prolonged, the hair root is stabilized, and the hair is fixed, in addition, the added blue copper peptide is responsible for improving microcirculation around the hair follicle, and acetyl tetrapeptide-5 promotes proliferation of hair papilla cells, so as to achieve the effect of hair growth.
A method for preparing a hair tonic composition, comprising the steps of:
s1, weighing water with a formula amount, heating to 60-80 ℃, adding 1, 2-butanediol, p-hydroxyacetophenone, dipotassium glycyrrhizinate, vitamin H, pyrimidine oxide derivatives, adenosine, nicotinamide, panthenol and hesperidin methyl chalcone with a formula amount, and stirring and mixing uniformly to obtain a mixed solution A;
s2, cooling the mixed solution A in the step S1 to 20-35 ℃, adding the hydrolyzed wheat protein, blue copper peptide, acetyl tetrapeptide-5, doctor tea and 17-type collagen according to the formula amount, and continuously stirring and uniformly mixing to obtain the hair-fixing and developing composition.
Compared with the prior art, the invention has the beneficial effects that:
(1) The hair-fixing and developing composition maintains the functions of hair follicle stem cells by adding 17-type collagen, and the linear aspartame extract contained in the doctor tea can inhibit the apoptosis of hair follicle stem cells and hair papilla cells, improve the environment around hair follicles and strengthen hair follicles; the growing period of hair follicles is prolonged, hair roots are stabilized to achieve the effect of hair fixation, in addition, the added blue copper peptide is responsible for improving microcirculation around the hair follicles, and acetyl tetrapeptide-5 promotes proliferation of hair papilla cells to achieve the effect of hair growth;
(2) The composition can provide necessary trace element nutrition for each stage of hair growth, shortens the progress of hair from a resting stage to a growing stage, delays the conversion from the growing stage to a withdrawal stage, effectively repairs scalp hair follicle injury, promotes hair growth, nourishes and fixes hair, and prevents hair from falling off;
(3) The pyrimidine oxide has better water solubility due to enhanced hydrophilicity, can better play the anti-drop effect, improves the bacteriostasis by the conjugation effect formed between the pyrimidine ring and the benzene ring after the benzene ring is introduced, and can reduce the phenomena of inflammation, alopecia and the like caused by bacterial reproduction.
Detailed Description
The technical scheme of the present invention will be described in detail by means of specific examples, which should be explicitly set forth for illustration, but should not be construed as limiting the scope of the present invention.
The parameters of partial raw materials in the embodiment of the invention are as follows:
hydrolyzed wheat protein with 99% purity, jiang Xihua, a source of biosciences limited.
Blue copper peptide with purity of 98%, shenzhen Haodihua Biotechnology Co., ltd.
Acetyl tetrapeptide-5 with purity not less than 98% is obtained from orthopeptides Biochemical technology (Nanjing) Co., ltd.
Type 17 collagen, shanghai Gejia Biotechnology Co.
2,6-bis (dimethylaminomethyl) -4-phenyl-5-hydroxypyrimidine 1-Oxide, 2,6-Bis (dimethylaminomethyl) -4-phenyl-5-hydroxy-pyrimide 1-Oxide, CAS:88467-03-2.
2-methyl-4-phenylpyrimidine 1-oxide, 2-methyl-4-phenylpyrimide 1-oxide, CAS:69098-69-7.
4, 6-diphenylpyrimidine-1-oxide, 4, 6-Diphenyl-pyrimid-1-oxide, CAS:60545-98-4.
4-Phenyl-5-hydroxypyrimidine 1-Oxide, 4-Phenyl-5-hydroxy pyrimide 1-Oxide, CAS:88070-45-5.
2- [ (dimethylamino) methyl ] -1-oxo-4-phenyl-1-pyrimidinium-5-ol, 2- [ (dimethyl-lamino) methyl ] -1-oxo-4-phenylpyrimidin-1-ium-5-ol, CAS:88475-57-4.
Comparative example 1
A method for preparing a hair tonic composition, comprising the steps of:
s1, taking 7.44L of water, heating to 65 ℃, adding 0.5kg of 1, 2-butanediol, 0.05kg of p-hydroxyacetophenone, 5g of dipotassium glycyrrhizinate, 5g of vitamin H, 0.1kg of 2, 4-diaminopyrimidine-3-oxide, 0.1kg of adenosine, 0.2kg of nicotinamide, 0.5kg of panthenol and 0.2kg of hesperidin methyl chalcone, and uniformly stirring and mixing to obtain a mixed solution A;
s2, cooling the mixed solution A in the step S1 to 25 ℃, adding 0.1kg of hydrolyzed wheat protein, 0.1kg of blue copper peptide, 0.1kg of acetyl tetrapeptide-5, 0.5kg of doctor tea and 0.1kg of 17-type collagen, and continuously stirring and uniformly mixing to obtain the hair-fixing and growing composition.
Example 1
A method for preparing a hair tonic composition, comprising the steps of:
s1, taking 7.44L of water, heating to 65 ℃, adding 0.5kg of 1, 2-butanediol, 0.05kg of p-hydroxyacetophenone, 5g of dipotassium glycyrrhizinate, 5g of vitamin H, 0.1kg of 2,6-bis (dimethylaminomethyl) -4-phenyl-5-hydroxypyrimidine 1-oxide, 0.1kg of adenosine, 0.2kg of nicotinamide, 0.5kg of panthenol and 0.2kg of hesperidin methyl chalcone, and uniformly stirring and mixing to obtain a mixed solution A;
s2, cooling the mixed solution A in the step S1 to 25 ℃, adding 0.1kg of hydrolyzed wheat protein, 0.1kg of blue copper peptide, 0.1kg of acetyl tetrapeptide-5, 0.5kg of doctor tea and 0.1kg of 17-type collagen, and continuously stirring and uniformly mixing to obtain the hair-fixing and growing composition.
Example 2
A method for preparing a hair tonic composition, comprising the steps of:
s1, taking 7.44L of water, heating to 65 ℃, adding 0.5kg of 1, 2-butanediol, 0.05kg of p-hydroxyacetophenone, 5g of dipotassium glycyrrhizinate, 5g of vitamin H, 0.1kg of 2-methyl-4-phenylpyrimidine 1-oxide, 0.1kg of adenosine, 0.2kg of nicotinamide, 0.5kg of panthenol and 0.2kg of hesperidin methyl chalcone, and uniformly stirring and mixing to obtain a mixed solution A;
s2, cooling the mixed solution A in the step S1 to 25 ℃, adding 0.1kg of hydrolyzed wheat protein, 0.1kg of blue copper peptide, 0.1kg of acetyl tetrapeptide-5, 0.5kg of doctor tea and 0.1kg of 17-type collagen, and continuously stirring and uniformly mixing to obtain the hair-fixing and growing composition.
Example 3
A method for preparing a hair tonic composition, comprising the steps of:
s1, taking 7.44L of water, heating to 65 ℃, adding 0.5kg of 1, 2-butanediol, 0.05kg of p-hydroxyacetophenone, 5g of dipotassium glycyrrhizinate, 5g of vitamin H, 0.1kg of 4,6-diphenyl pyrimidine-1-oxide, 0.1kg of adenosine, 0.2kg of nicotinamide, 0.5kg of panthenol and 0.2kg of hesperidin methyl chalcone, and uniformly stirring and mixing to obtain a mixed solution A;
s2, cooling the mixed solution A in the step S1 to 25 ℃, adding 0.1kg of hydrolyzed wheat protein, 0.1kg of blue copper peptide, 0.1kg of acetyl tetrapeptide-5, 0.5kg of doctor tea and 0.1kg of 17-type collagen, and continuously stirring and uniformly mixing to obtain the hair-fixing and growing composition.
Example 4
A method for preparing a hair tonic composition, comprising the steps of:
s1, taking 7.44L of water, heating to 65 ℃, adding 0.5kg of 1, 2-butanediol, 0.05kg of p-hydroxyacetophenone, 5g of dipotassium glycyrrhizinate, 5g of vitamin H, 0.1kg of 4-phenyl-5-hydroxypyrimidine 1-oxide, 0.1kg of adenosine, 0.2kg of nicotinamide, 0.5kg of panthenol and 0.2kg of hesperidin methyl chalcone, and uniformly stirring and mixing to obtain a mixed solution A;
s2, cooling the mixed solution A in the step S1 to 25 ℃, adding 0.1kg of hydrolyzed wheat protein, 0.1kg of blue copper peptide, 0.1kg of acetyl tetrapeptide-5, 0.5kg of doctor tea and 0.1kg of 17-type collagen, and continuously stirring and uniformly mixing to obtain the hair-fixing and growing composition.
Example 5
A method for preparing a hair tonic composition, comprising the steps of:
s1, taking 7.44L of water, heating to 65 ℃, adding 0.5kg of 1, 2-butanediol, 0.05kg of p-hydroxyacetophenone, 5g of dipotassium glycyrrhizinate, 5g of vitamin H, 0.1kg of 2- [ (dimethylamino) methyl ] -1-oxo-4-phenyl-1-pyrimidinium-5-ol, 0.1kg of adenosine, 0.2kg of nicotinamide, 0.5kg of panthenol and 0.2kg of hesperidin methyl chalcone, and uniformly stirring and mixing to obtain a mixed solution A;
s2, cooling the mixed solution A in the step S1 to 25 ℃, adding 0.1kg of hydrolyzed wheat protein, 0.1kg of blue copper peptide, 0.1kg of acetyl tetrapeptide-5, 0.5kg of doctor tea and 0.1kg of 17-type collagen, and continuously stirring and uniformly mixing to obtain the hair-fixing and growing composition.
Test example 1
Healthy male rats are selected, the body mass is 180-220 g, the age is 6 weeks, and the mice are randomly divided into groups: normal, model, 6 experimental groups of 8 animals each. After the mice are subjected to adaptive culture for one week, the back hair of the mice is removed 1d before the experiment, testosterone (5 mg/kg.d) is smeared on the backs of the other mice except the normal mice, and the mice are subjected to continuous treatment for 28d. The experimental group is corresponding to the application of each hair-setting composition on the back skin of a mouse, the application of the same volume of physiological saline to the model group and the normal group is 0.2mL, and the growth conditions of the back skin and hair of the mouse are observed every day. After 28d, 30 hairs were pulled out from 3 different parts of the shaving area, the length was measured and recorded, the back skin was removed by killing the mice, the surface hairs were shaved off and weighed and recorded, and the average value was taken, and specific experimental data are shown in table 1.
Table 1 results of experiments on the effect of hair growth in mice
Hair follicles can self-renew, and grow periodically, and are divided into a growing period, a retrograde period and a resting period. The growth phase of human hair follicles can generally last for 2-7 years, the catagen phase is only 2-3 weeks, and the rest phase is on average 3 months. Hair follicles in anagen phase mainly synthesize DNA and produce melanin, hair follicle DNA synthesis is completely stopped and melanin production is discontinued during telogen phase. The hair-setting composition has therapeutic effect on androgen alopecia model mice, and can promote telogen hair follicles in the back skin of the mice to enter the anagen phase more quickly, so that the hair grows more quickly. The aminopyrimidine oxide can inhibit lysine hydroxylase, prevent synthesis of mature collagen around hair follicle, prevent hair follicle from hardening and shrinking, and prevent alopecia; the 17-type collagen can maintain the function of hair follicle stem cells, and the linear aspartame extract contained in the doctor tea can inhibit the apoptosis of hair follicle stem cells and hair papilla cells, improve the environment around hair follicles and strengthen the hair follicles; in addition, the added blue copper peptide is responsible for improving microcirculation around hair follicles, acetyl tetrapeptide-5 promotes proliferation of hair papilla cells to achieve the effect of hair growth, so that the hair growth conditions of mice in experimental groups can be seen to be better, however, the difference of hair length and weight in mice in each group is still obvious, which is probably caused by different pyrimidine oxide derivatives, the pyrimidine ring has hydrophilic groups, and the hydrophilic groups are better, so that the hair growth can be better performed in the composition, and the 2 tertiary amino groups and the hydroxyl groups in the 2,6-bis (dimethylaminomethyl) -4-phenyl-5-hydroxypyrimidine 1-oxide structure in the embodiment 1 are more hydrophilic than the amino groups, which are mainly beneficial to the fact that the polarities of the two are higher, and the hydrogen bond formation with water molecules is easy, so that the effect of hair growth is improved, and the hair growth is more obvious.
Test example 2
Determining influence of hair growth promoting composition on hair papilla cell viability by CCK-8 method, digesting hair papilla cells with 1mL trypsin solution with mass fraction of 0.25% for 3min, adding DMEM complete culture medium to stop digestion, centrifuging at 1000r/min for 5min, removing supernatant, adding DMEM complete culture medium to resuspend cells, inoculating hair papilla cells into 96 well plate with cell density of 1×10 4 After the hair papilla cells are attached to each hole, adding a complete culture medium into a control group, respectively adding 100 mu L of culture medium of the hair-setting and developing composition in each example into an experimental group, culturing for 48 hours, adding 10 mu L of CCK-8 reagent into each hole, and adding 5% CO at 37 ℃ in mass fraction 2 Culturing for 2h under the condition, measuring OD value at 450nm wavelength, measuring the activity of hair papilla cells, and calculating the cell survival rate, wherein the specific result is shown in Table 2.
TABLE 2 results of the effects of hair growth promoting composition on hair papilla cell viability
| Experimental protocol | Hair papilla cell viability/% |
| Control group | 100.0 |
| Comparative example 1 | 112.5 |
| Example 1 | 139.1 |
| Example 2 | 110.4 |
| Example 3 | 110.0 |
| Example 4 | 129.7 |
| Example 5 | 134.2 |
Papilla cells are key cells for hair production and secrete a variety of cytokines that regulate hair growth. The in vitro cell experiment result proves that the hair-fixing and developing composition prepared by the invention can promote the proliferation of hair papilla cells and is beneficial to hair growth. The survival rate of hair papilla cells can show that the prepared hair-setting and developing composition can effectively promote proliferation of hair papilla cells, so that the composition can effectively resist alopecia, stimulate hair follicle to regenerate, optimize hair cycle, promote growth phase, shorten resting phase and accelerate new hair growth. The hair-fixing and developing composition maintains the functions of hair follicle stem cells by adding 17-type collagen, and the linear aspartame extract contained in the doctor tea can inhibit the apoptosis of hair follicle stem cells and hair papilla cells, improve the environment around hair follicles and strengthen hair follicles; the growth period of hair follicle is prolonged, the hair root is stabilized, and the hair is fixed, in addition, the added blue copper peptide is responsible for improving microcirculation around the hair follicle, and acetyl tetrapeptide-5 promotes proliferation of hair papilla cells, so as to achieve the effect of hair growth.
Test example 3
Performing bacteriostasis experiments on the solid and developing hair compositions prepared in the comparative examples and the examples, wherein the selected other strain is pityrosporum Ma Laxuan (ATCC 1452), and absorbing 200 mu L of indicator bacteria suspension under the aseptic condition and uniformly coating the indicator bacteria suspension on a flat plate culture medium; to oxford cups were added dropwise 0.1mL of the sample solutions from examples and comparative examples, respectively, while the control group was not added dropwise. Wherein the culturing of the indicator bacteria is malassezia is based on 37 ℃ for 48 hours; and removing the oxford cup, precisely measuring the diameter of each bacteriostasis ring by using a vernier caliper, and comparing the bacteriostasis effect.
TABLE 3 antibacterial effect of hair-setting and developing compositions
| Experimental protocol | Diameter/mm of inhibition zone |
| Control group | 5.65 |
| Comparative example 1 | 15.81 |
| Example 1 | 19.93 |
| Example 2 | 16.34 |
| Example 3 | 18.47 |
| Example 4 | 16.12 |
| Example 5 | 16.03 |
When the scalp excessively secretes sebum, the excessive sebum is acted on by microorganisms to produce fatty acids, which stimulate the scalp to produce inflammation, wherein the microorganisms which play a major role are malassezia. Hydrolysis of triacylglycerols secreted by sebaceous glands by esterases depletes saturated fatty acids, releases irritating unsaturated fatty acids (e.g. octadecenoic acid), leads to a decrease in the degree of compaction of the skin adipose tissue, thus affecting the skin barrier function, ultimately leading to symptoms of inflammation and alopecia. Dipotassium glycyrrhizinate belongs to pentacyclic triterpene compounds, has stronger antibacterial activity, besides good antibacterial effect, dipotassium glycyrrhizinate also has the effect of inhibiting inflammation, and antibacterial experiments show that the prepared hair-setting composition has a certain antibacterial effect, and the antibacterial activity in the embodiment is stronger, which means that besides the antibacterial effect of dipotassium glycyrrhizinate, pyrimidine oxide derivatives also have a certain antibacterial effect, the structural difference of different pyrimidine oxide derivatives has a certain influence on the antibacterial property, the water solubility of the pyrimidine oxide derivatives also directly influences the exertion of the antibacterial effect in the composition, the phenyl connected with pyrimidine rings enhances the antibacterial activity of the derivatives, and the antibacterial principle is that an active substance can cause the rupture of microbial cell walls or cell membranes or the action of certain enzymes or metabolites generated by microbial cells, so that the enzyme inactivation or the interruption of metabolic chains is caused, and the electron transfer plays a very important role in the process, and the pyrimidine oxide can provide electrons and also accept electrons, so that the conjugated effect formed between the pyrimidine rings and benzene rings after the benzene rings is introduced, the activity is improved, so that the hair-setting composition in the embodiment can inhibit the hair-setting composition from growing and removing the hair-setting effect of the hair-setting composition can be achieved.
Claims (8)
1. A hair tonic composition comprising the following components: 1, 2-butanediol, p-hydroxyacetophenone, dipotassium glycyrrhizinate, vitamin H, pyrimidine oxide derivatives, adenosine, nicotinamide, panthenol, hesperidin methyl chalcone, hydrolyzed wheat protein, blue copper peptide, acetyl tetrapeptide-5, doctor tea, type 17 collagen and water.
2. The composition of claim 1, comprising the following components in percentage by mass: 0.1 to 10 percent of 1, 2-butanediol, 0.1 to 1 percent of p-hydroxyacetophenone, 0.01 to 1 percent of dipotassium glycyrrhizinate, 0.001 to 1 percent of vitamin H, 0.1 to 1.5 percent of pyrimidine oxide derivative, 0.05 to 5 percent of adenosine, 0.05 to 10 percent of nicotinamide, 0.01 to 10 percent of panthenol, 0.05 to 3 percent of hesperidin methyl chalcone, 0.001 to 5 percent of hydrolyzed wheat protein, 0.001 to 5 percent of blue copper peptide, 0.001 to 5 percent of acetyl tetrapeptide-5, 0.001 to 10 percent of doctor tea, 0.001 to 20 percent of 17-type collagen and the balance of water.
3. The composition of claim 1, wherein: the pyrimidine oxide derivative comprises at least one of 2,6-bis (dimethylaminomethyl) -4-phenyl-5-hydroxypyrimidine 1-oxide, 2-methyl-4-phenylpyrimidine 1-oxide, 4, 6-diphenylpyrimidine 1-oxide, 4-phenyl-5-hydroxypyrimidine 1-oxide, 2- [ (dimethylamino) methyl ] -1-oxo-4-phenyl-1-pyrimidinium-5-ol.
4. A process for preparing a composition according to any one of claims 1 to 3, comprising the steps of:
s1, weighing water with a formula amount, heating, adding 1, 2-butanediol, p-hydroxyacetophenone, dipotassium glycyrrhizinate, vitamin H, pyrimidine oxide derivatives, adenosine, nicotinamide, panthenol and hesperidin methyl chalcone with a formula amount, and stirring and mixing uniformly to obtain a mixed solution A;
s2, cooling the mixed solution A in the step S1, adding the hydrolyzed wheat protein, the blue copper peptide, the acetyl tetrapeptide-5, the doctor tea and the 17-type collagen according to the formula amount, and continuously stirring and uniformly mixing to obtain the hair-fixing and growing composition.
5. A method of preparing the composition of claim 4, wherein: the heating temperature in the step S1 is in the range of 60-80 ℃.
6. A method of preparing the composition of claim 4, wherein: the temperature range of the temperature reduction in the step S2 is 20-35 ℃.
7. Use of a composition according to any one of claims 1 to 3 for anti-hair loss hair growth care.
8. Use of a composition according to claim 7, wherein the composition is added in an amount of 5 to 35wt%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310304218.5A CN116350535A (en) | 2023-03-27 | 2023-03-27 | Hair-fixing and developing composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310304218.5A CN116350535A (en) | 2023-03-27 | 2023-03-27 | Hair-fixing and developing composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116350535A true CN116350535A (en) | 2023-06-30 |
Family
ID=86913984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310304218.5A Pending CN116350535A (en) | 2023-03-27 | 2023-03-27 | Hair-fixing and developing composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116350535A (en) |
-
2023
- 2023-03-27 CN CN202310304218.5A patent/CN116350535A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3108586B2 (en) | Hair restorer | |
| WO2013027984A2 (en) | Cosmetic composition containing green tea component | |
| TW200306209A (en) | Medicament for curing itching rough skin or sensitive skin and for skin whitening based on reducing production and/or release of stem cell factor | |
| KR20100116882A (en) | Composition for promoting hair growth comprising extract or a saponin fraction of codonopis lanceolata | |
| CN116209425A (en) | Composition for preventing alopecia and promoting hair growth | |
| CN106937957B (en) | Composition for treating androgenetic alopecia and shampoo thereof | |
| CN110064039B (en) | Anti-hair loss and hair-nourishing composition and application thereof | |
| KR101830864B1 (en) | Cosmetic composition for inhibiting hair loss and enhanching hair growth | |
| CN116350535A (en) | Hair-fixing and developing composition and application thereof | |
| KR101167510B1 (en) | Composition for preventing hair loss or promoting hair growth comprising an saponin biotransformant of Ginseng | |
| KR101273027B1 (en) | Composition for inhibiting sebum secretion and anti-obesity comprising kaempferol | |
| JP3908245B2 (en) | Hair nourishing agent | |
| KR20050102346A (en) | Hair growth agent composition | |
| JP3357746B2 (en) | Hair restorer | |
| KR102348696B1 (en) | Cosmetic composition comprising teprenone | |
| KR102354282B1 (en) | Cosmetic composition comprising erythorbic acid | |
| EP3888625A1 (en) | Composition for scalp and hair | |
| KR20150025984A (en) | Composition for promoting hair growth or restoration containing 21-o-angeloyltheasapogenol e3 | |
| CN115554380B (en) | Composition for preventing and treating alopecia by acting on hair follicle tissue and application thereof | |
| JP2002212039A (en) | Gray hair preventing agent | |
| KR102093708B1 (en) | A cosmetic composition using Fraxini cortex extract | |
| JP3260909B2 (en) | Hair restorer | |
| JP7411196B2 (en) | Type XVII collagen maintenance and enhancement agent | |
| KR20110101727A (en) | Composition for improving skin wrinkle | |
| KR20090059230A (en) | Cosmetic composition for anti-alopecia and trichogenousness |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20231225 Address after: 310000 room 602, 6 / F, building 1, Dongzhan Xizi international, No. 777, huanzhan East Road, Jianggan District, Hangzhou City, Zhejiang Province Applicant after: Hangzhou Youli medical technology (Group) Co.,Ltd. Address before: 310000 room 602, 6 / F, building 1, Dongzhan Xizi international, No. 777, huanzhan East Road, Jianggan District, Hangzhou City, Zhejiang Province Applicant before: Hangzhou Fuyin Biotechnology Co.,Ltd. |
|
| TA01 | Transfer of patent application right |